ArticleScientific reports2025
Prediction of aggregation in monoclonal antibodies from molecular surface curvature.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Review on Applications of Artificial Intelligence (AI) in Monoclonal Antibody (mAb) Manufacturing.Molecules (Basel, Switzerland) · 2026Review
- Phage Display Technology: Design, Library Construction, and Panning Strategies for Antibody Development.Biomolecules & therapeutics · 2026Review
- Characterization of Conformational Instability of Monoclonal Antibodies During Chromatographic Purification.International journal of molecular sciences · 2026Review
- Emerging Technologies and Integrated Interdisciplinary Strategies for Mitigating Protein Aggregation in Therapeutic Formulations.Pharmaceutical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Protein aggregation is one of the key challenges in the biopharmaceutical industry as its control is crucial in achieving long-term stability and efficacy of biopharmaceuticals. Attempts have been made to develop regression models for predicting the aggregation of monoclonal antibodies in solution using machine learning methods. These efforts have yielded varying levels of success, with current state-of-the-art AI approaches achieving good prediction accuracies ([Formula: see text]). Here, we demonstrate the prediction of aggregation rate in monoclonal antibodies with beyond state-of-the-art reliability using a coupled AI-MD-Molecular surface curvature modelling platform. The scientific novelty of this approach lies in using local geometrical surface curvature of proteins as the core element for protein stability analysis. By combining local surface curvature and hydrophobicity, as derived from time-dependent MD simulations, we are able to construct aggregation predictive features that, when coupled with linear regression machine learning techniques, give a high prediction accuracy ([Formula: see text]) on a dataset of 20 molecules. More generally, this approach shows significant potential for quantitative in silico screening and prediction of protein aggregation, which is of great scientific and industrial relevance, particularly in biopharmaceutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.